| Document |
Document Title |
|
WO/2001/005748A1 |
The current invention discloses novel oligomeric amidino aminocarboxylate derivatves useful as nitric oxide synthase inhibitors.
|
|
WO1999064049A9 |
This invention relates to novel multibinding compounds (agents) that are antibacterial agents. The multibinding compounds of the invention comprise from 2-10 ligands covalently connected by a linker or linkers, wherein each of said ligan...
|
|
WO/2001/004106A1 |
A process for producing dibenzothiazepine derivatives typified by dibenzo[b,f][1,4]thiazepin-11-one which are usable as the starting material for producing 11-[4-(2-(2-hydroxyethoxy)ethyl)]-1-piperazinyldibenzothiaze
pine derivatives use...
|
|
WO/2001/002344A1 |
Aminobenzoic acid derivatives represented by general formula (1) or pharmaceutically acceptable salts thereof which are usable as VEGF receptor antagonists, in particular, remedies for diseases in which VEGF participates wherein R?1¿ re...
|
|
WO/2001/002032A1 |
The invention relates to an ophthalmic molding such as a contact lens or any kind of ocular prostheses comprising an organic bulk material having covalently bonded to its surface an acceptor saccharide to which is enzymatically attached ...
|
|
WO/2001/001979A1 |
Compounds of formula (I) and pharmaceutically acceptable salts thereof in which m is 0, 1 or 2; n is 2, 3, 4 or 5; X is carbonyl or a group of formula (II) in which R¿5? is H or alkyl; Y is an alkylene chain optionally substituted by on...
|
|
WO/2001/000566A2 |
Disclosed are substituted phenoxyacetic acids useful in the treatment of chronic complications arising from diabetes mellitus. Also disclosed are pharmaceutical compositions containing the compounds, alone or in combination with other th...
|
|
WO/2001/000608A1 |
Racemic or optically pure N-(4-cyano-3-trifluoromethylphenyl)-3-(4 -fluorophenylsulphonyl)-2-hydroxy-2-methylpropionamide of formula (I) is prepared by the following process: 2,3-dihydroxy-2-methylpropionic acid of formula (VII) is react...
|
|
WO/2001/000579A1 |
Modulators of PPAR$g(g) activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.
|
|
WO/2001/000568A1 |
Compounds of general formula (I) and salts and solvates of the same. In said formula, R?1¿, R?2¿, R?3¿, R?4¿ and R?5¿ are each hydrogen, halogeno, optionally substituted alkyl, or optionally substituted phenyl, provided that all of ...
|
|
WO/2000/077169A2 |
Compounds of formula (I) are provided wherein R¿1?, R¿2?, R¿3? and R¿4? are independently selected from the group consisting of hydrogen, halogen, hydroxyl, C¿1?-C¿8? alkyl, C¿1?-C¿6? alkoxy, nitro, cyano, acetoxy, amino, carboxy...
|
|
WO/2000/076962A1 |
Thiol derivative compounds, pharmaceutically acceptable salts, and biolabile esters thereof, useful for inhibiting metallo-$g(b)-lactamases, bacterial enzymes which confer resistance to clinically relevant ß-lactam antibiotics, characte...
|
|
WO/2000/074705A1 |
The invention relates to the utilization of reaction products as antigens for the diagnosis and therapy of rheumatic autoimmune diseases, especially rheumatic arthritis. Said reaction products are obtained by reacting proteins and/or pep...
|
|
WO/2000/075105A1 |
Molecules comprising aminooxy groups are provided, wherein the aminooxy groups provide attachment sites for the covalent attachment of other molecules. In one embodiment, polyoxyethylene molecules comprising aminooxy groups are provided ...
|
|
WO/2000/075103A1 |
Novel substituted phenylpropionic acid derivatives capable of binding as a ligand to human peroxisome proliferator-activated receptor $g(a) (PPAR$g(a)) to thereby activate the receptor and thus showing a potent effect of lowering blood l...
|
|
WO/2000/075101A1 |
Compounds of formula (I) in which R?1¿ is halo-C¿1-10? alkyl; halo-C¿2-10? alkenyl; or (CH¿2?)¿n?Y in which n is 1 or 2 and Y is OH, CN, N¿3?, OR?3¿, SH, S(O)¿p?R?4¿, S(O)¿3?H, NH¿2?, NHR?5¿, NR?6¿R?7¿, NHCOR?8¿, NO¿2?, C...
|
|
WO/2000/073289A1 |
The invention relates to novel aryl-substituted S(O)¿m? cycles of formula (I), in which F?1¿, F?2¿, G, V, W, X, Y, Z and m have the meanings defined in the description. The invention further relates to methods for producing said cycle...
|
|
WO/2000/073266A1 |
The invention concerns compounds of general formula (I) (wherein R and R' represent an alkyl radical or an aryl group and R'' is hydrogen or a CO-R?1¿ group wherein R?1¿ is an alkyl radical or an aryl group; and the dimers formed by th...
|
|
WO/2000/073265A1 |
The present disclosure describes novel compounds of formula (A), wherein R¿1?-R¿12?, X and Y have the meanings given in the specification and compositions containing them which are particularly useful for treating hair loss in mammals,...
|
|
WO/2000/073796A2 |
The invention relates to sensors for detecting molecular interactions between immobilized ligands and non-immobilized interaction partners (receptors). These surfaces use novel ligand-anchor conjugates that allow a highly specific intera...
|
|
WO/2000/073258A1 |
Derivatives of active ingredients with amino acids are disclosed having enhanced nutritional and/or therapeutic effects which favourably lend themselves to the preparation of orally administrable solid compositions.
|
|
WO/2000/073264A1 |
Compounds having formula (I), inhibit cellular proliferation. Processes for the preparation of the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.
|
|
WO/2000/071500A1 |
The invention relates to novel halogen compounds, to a method for producing them and to their use for treating plants for protecting them against attack from phytopathogenic microorganisms and insects. The invention also relates to novel...
|
|
WO/2000/071520A2 |
Patients susceptible to or suffering from conditions and disorders, such as central nervous system disorders, are treated by administering to a patient in need thereof aryloxyalkylamines and arylthioalkylamines, including pyridyloxylalky...
|
|
WO/2000/071785A2 |
A compound of general formula (I) wherein: R?1¿ is C¿3-6? cycloalkyl optionally substituted with one or more C¿1-4? alkyl groups; R?2¿ is a C¿1-10? alkyl group, optionally substituted with one or more halo or C¿1-4? alkoxy substitu...
|
|
WO/2000/071514A1 |
A family of molecules of formula (A) in which R?1¿ is a 5- or 6-membered carbocyclo, heterocyclo, aryl or heteroaryl radical such that its size defined by certain parameters; R?20¿ is -O-R?21¿, -NR?13¿-O-R?22¿ or -NR?13¿-O-R?14¿; ...
|
|
WO/2000/069800A2 |
The invention relates to a process for preparing compounds of formula (I), wherein R?1¿ and R?2¿ are as defined in the description.
|
|
WO/2000/069810A1 |
A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or preventio...
|
|
WO/2000/068218A1 |
Photoinitiators of formula (Ia) or (Ib) having chain transfer groups, wherein n is 1 or 2; PI is for example a group of formula (IIa); PI' inter alia is a group of formula (IIIa); Ar is for example phenyl; Ar¿2? is inter alia phenylene;...
|
|
WO/2000/068189A1 |
This invention provides fluorochemical compounds comprising: a fluorochemical oligomeric portion comprising an aliphatic backbone with a plurality of pendant fluoroaliphatic groups, each fluoroaliphatic group having a fully fluorinated t...
|
|
WO/2000/066528A2 |
Novel quinones are provided, as well as compositions comprising these novel quinones. Methods of using the novel quinones in treatment of various indications including cancer are also provided.
|
|
WO/2000/065913A1 |
Microbicides for agricultural and horticultural use, containing sulfonamide derivatives such as compounds of general formula (I) or salts thereof; some of the derivatives; and processes for the preparation of the same. In said formula, A...
|
|
WO/2000/066545A1 |
The invention concerns compounds of general formula (I) wherein: R¿1? represents either a hydrogen atom, or an amino group, or a C¿1?-C¿4? alkyl group, or a C¿1?-C¿6? alkoxycarbonyl group, or a -OH group; R¿2? represents either a C...
|
|
WO/2000/066524A1 |
A D-mannitol derivative selected from the group consisting of a compound of formula (I) pharmaceutically acceptable derivatives thereof and where applicable or appropriate pharmaceutically acceptable salts thereof, wherein R¿1?, R¿2?, ...
|
|
WO/2000/066537A1 |
The present invention is directed to compounds of Formula (I) or pharmaceutically acceptable salts thereof; wherein X is hydrogen, C1, Br, I, NO¿2?, NR?3¿R?4¿ or -L-Ch; Y is hydrogen, -CH¿2?OR?5¿, -CH¿2?NCH¿3?R?1¿, NO¿2?, NR?3¿...
|
|
WO/2000/064484A2 |
Conjugates of a hydrophobic moiety, such as a lipid, linked through a cleavable dithiobenzyl linkage to a therapeutic agent are described. The dithiobenzyl linkage is susceptible to cleavage by mild thiolysis, resulting in release of the...
|
|
WO/2000/064848A1 |
The invention relates to a method for the dihydroxylation of olefins using transition-metal catalysts for producing monofunctional, bifunctional and/or polyfunctional 1,2 diols of the formula (I): R?1¿R?2¿C(OH)-C(OH)R?3¿R?4¿. Accordi...
|
|
WO/2000/064844A1 |
The invention relates to a method for the asymmetric dihydroxylation of olefins, using osmium catalysts for producing monofunctional, bifunctional and/or polyfunctional chiral 1,2 diols of formula (I): R?1¿R?2¿C(OH)-C(OH)R?3¿R?4¿. Ac...
|
|
WO/2000/064888A1 |
This invention is directed to diaryl acid derivatives of formula (I) and their pharmaceutical compositions as PPAR ligand receptor binders. The PPAR ligand receptor binders of this invention are useful as agonists or antagonists of the P...
|
|
WO/2000/063161A1 |
Disclosed are compounds of formula (I) or the pharmaceutically acceptable non-toxic salts thereof wherein: Z is aryl or heteroaryl; n and m are 0, 1 or 2; A is a carboxylic acid or ester; or A is formula (II) where D, F and G are hydroge...
|
|
WO/2000/063234A2 |
Compounds of formula (I) are described which have activity as anti-inflammatory agents. Cyclic disulfide compounds are provided which inhibit of binding of cells to endothelium. Such compounds are useful for treating inflammatory disease...
|
|
WO/2000/063165A1 |
The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP- or TNF $g(a)-mediated diseases.
|
|
WO/2000/061548A1 |
The N-substituted-N'-substituted urea derivative of formula (a), analogues of the same, or medicinally acceptable salts of both, having a TNF-production inhibiting effect.
|
|
WO/2000/061538A1 |
Methods for preparing substituted aromatic carboxylic acid esters are described. In particular, the invention relates a method for preparing a nitro-substituted aromatic carboxylic acid ester of Formula (A). Additionally the invention re...
|
|
WO/2000/061527A2 |
Enhanced synthesis of transition metal dithiolene complexes is described. [1,2-bis(Trifluoromethyl)ethylene-1,2-dithiolato]nickel selectively and reversibly binds olefins (C¿2? to C¿6?). Under the same conditions, the complex does not ...
|
|
WO/2000/059878A2 |
The present invention is directed to compounds that bind to a novel regulatory site in the I domain of LFA-1, and thereby inhibit LFA-1 binding to ICAMs that bind LFA-1. The present invention therefore also provides methods to regulate l...
|
|
WO/2000/059899A1 |
The invention concerns novel lipoic acid derivatives, which have an inhibiting action with respect to NO-synthase enzymes producing nitrogen monoxide NO and/or are agents enabling the regeneration of antioxidants or entities trapping rea...
|
|
WO/2000/059877A1 |
A process for the preparation of 2-hydroxy-4-methylthiobutyric acid ester which comprises (a) a first step of reacting 2-hydroxy-4-methylthiobutyronitrile with sulphuric acid to produce 2-hydroxy-4-methylthiobutyramide, and (b) a second ...
|
|
WO/2000/059867A1 |
An hydroxphenyl derivative selected from the group consisting of a compound of formula (I), (II) and comprises a carboxylic acid group when a compound of formula (I) pharmaceutically acceptable salts thereof and when a compound of formul...
|
|
WO/2000/059474A1 |
Novel lipid compounds are provided that may be termed 'pro-cationic' in that they are neutral or negatively charged until they are either brought into contact with cellular membranes or are internalized by cells. The lipids have a hydrop...
|
